Intellia Therapeutics Inc.

10/01/2024 | Press release | Distributed by Public on 10/01/2024 05:35

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.